– In clinical studies, more than half of patients receiving risankizumab achieved complete skin clearance (PASI 100) at one year (52 weeks) (1) – The Biologics License Application is supported by four Phase 3 studies of more than 2,000 patients with moderate to severe plaque psoriasis (1-3) – Risankizumab is an investigational compound designed to…
AbbVie, Neurocrine Announce Target Date for Elagolix in Endometriosis-associated Pain
Upadacitinib Meets All Primary and Ranked Secondary Endpoints in Phase 3 Study
Positive Topline Results from Second Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids
Positive Topline Results from Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids
AbbVie, Voyager Therapeutics Announce Global Collab to Develop New Treatments for Alzheimer’s Disease
FDA Grants AbbVie’s Upadacitinib Breakthrough Therapy Designation for Atopic Dermatitis
AbbVie Monotherapy Meets All Primary Endpoints In Rheumatoid Arthritis Study
AbbVie’s upadacitinib shows positive results as monotherapy in Phase 3 rheumatoid arthritis study, meeting all primary and key secondary endpoints. AbbVie, a global research and development-based biopharmaceutical company, announced positive top-line results from the Phase 3 SELECT-MONOTHERAPY clinical trial. The ongoing study evaluated upadacitinib (ABT-494), an investigational oral JAK1-selective inhibitor, as a monotherapy treatment in patients with moderate…